Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure

Table 5 Hemoglobin level and platelet count in the two treatment groups

Group	Number of patients	PLT count (× 109/L)		HGB level (g/L)
		Pre-treatment	Post-treatment	Pre-treatment	Post-treatment
Observation group	33	41.23 ± 2.08	41.45 ± 2.56	96.58 ± 1.23	96.88 ± 1.11
Control group	32	41.45 ± 1.98	41.88 ± 2.43	96.45 ± 1.08	96.78 ± 1.37
t	-	0.436	0.694	0.452	0.323
P value	-	0.664	0.490	0.652	0.747

Data are presented as mean ± SD. PLT: Platelet; HGB: Hemoglobin.